Wise men on the street will tell you it is foolish to try and time the market. And attempting to do so in the midst of a raging war is prob...

Biocon shares rose after a block deal involving around 1.65 crore shares. Investor Active Pine was reportedly looking to sell up to 1.66 cr...

Active Pine is likely to sell up to 1.66 crore Biocon shares, worth Rs 638 crore, through a block deal at Rs 385 per share. The development...

Another worry has emerged for the markets, and it will drive the narrative in the short term. As usual, it comes from the US. The US Fed ha...

During the first quarter of fiscal 2027, India's pharmaceutical exports soared to $8.10 billion, showcasing remarkable strength in drug for...

For Indian pharma, the regulatory risk is still real. A US FDA inspection can still cause trouble. A plant making an important product or g...

The threat of a US tariff on Indian pharma is no longer a vague fear; or at least that is what President Trump wants us to believe. There i...

Indian per capita income increase will lead to increased spending on healthcare and medicines, including both generic and non-generic produ...

Under the scheme, financial incentives will be given to eligible manufacturers of complex generics and biopharmaceuticals on their sales ov...

Biosimilars to biologic drugs are what generics are to chemical drugs.

The drug firm is banking on the introduction of complex generics and biosimilars in the US to maintain its top five position in the market.

While sustaining and growing its presence in the generics segment, Lupin is planning to invest heavily in developing high barrier products ...

"Our clinical data package has been approved by ODAC recently, and the GMP part of the regulatory process has already seen us-- provide a s...

Biosimilars are follow-on versions of biologic drugs and far more complex and more difficult to copy than generic drugs because of the stru...

The Indian biogenerics industry is poised to exploit the opportunity they did in the case of generics, although it has no clear advantage a...

Two years after announcing a JV with Mylan, Biocon has revealed the potential of its drugs under the biologics deal with Mylan.

India's largest drug maker, Dr Reddy’s Laboratories, is planning to introduce its first biosimilar drug by 2010 in Europe, a senior company...